TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Molecular diagnosis of CP CML of ≤ 6 months (from initial diagnosis).~2. Adequate hepatic, renal and pancreatic function.~3. Age ≥ 18 years.~Exclusion Criteria:~1. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with the exception of hydroxyurea and/or anagrelide treatment, which are permitted for up to 6 months prior to study entry (signature of ICF) if suitably approved for use in the subject's region.~2. Any past or current Central Nervous System (CNS) involvement, including leptomeningeal leukemia.~3. Extramedullary disease only.~4. Major surgery or radiotherapy within 14 days of randomization.~5. History of clinically significant or uncontrolled cardiac disease.~6. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, cirrhosis or evidence of decompensated liver disease. Patients with resolved Hepatitis B can be included.~7. Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease, Ulcerative Colitis, or prior total or partial gastrectomy.~8. History of another malignancy within 5 years with the exception of basal cell carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least l2 months.~9. Current, or recent (within 30 days, or 5 half-lives of investigational product) participation in other clinical trials of investigational agents and/or containing interventional procedures deemed contrary to the objectives and conduct of this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosutinib (Type: EXPERIMENTAL): Bosutinib, 400 mg, oral administration once a day
- Imatinib (Type: ACTIVE_COMPARATOR): Imatinib, 400 mg, oral administration once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria (not including amenorrhea) for AN~* Body mass index (BMI) less than 19 kg/m2 and greater than 14 kg/m2~* Patient (or family if the patient is a minor) refuses hospitalization~* Free of psychotropic medication (4 weeks medication free for fluoxetine and antipsychotic medication; 2 weeks medication free for all others) OR on a stable dose of an SSRI or SNRI (venlafaxine) for 4 weeks before study entry~* Prior treatment of AN~Exclusion Criteria:~* Any medical or psychiatric problem requiring urgent attention and/or any significant comorbid illness not likely to benefit from proposed treatments~* Allergy to olanzapine~* Significant orthostatic high blood pressure~* Recent commencement of psychotherapy in the community~* Diabetes mellitus, with a fasting serum glucose greater than 120 mg/dL or nonfasting serum glucose greater than 140 mg/dL~* Known history of current or past jaundice~* Known history of narrow angle glaucoma~* Active substance abuse or dependence~* Schizophrenia, schizophreniform disorder, or bipolar illness~* Movement disorder or presence of tics~* History of tardive dyskinesia~* History of seizures~* Pregnant

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will take olanzapine.
- 2 (Type: PLACEBO_COMPARATOR): Participants will take matched placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18, with chronic genotype 1 HCV infection~* HCV treatment-naive~* HCV RNA \> 10,000 IU/mL at screening~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Co-infection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 weeks (Type: EXPERIMENTAL): LDV/SOF administered for 12 weeks
- LDV/SOF+RBV 12 weeks (Type: EXPERIMENTAL): LDV/SOF+RBV administered for 12 weeks.
- LDV/SOF 24 weeks (Type: EXPERIMENTAL): LDV/SOF administered for 24 weeks
- LDV/SOF+RBV 24 weeks (Type: EXPERIMENTAL): LDV/SOF+RBV administered for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key inclusion criteria:~1. Documented history of migraine in the 12 months prior to screening~2. 4-14 days per month of migraine symptoms~3. \>=80% diary compliance during the Baseline period~Key exclusion criteria:~1. \>50 years old at migraine onset~2. Pregnant or nursing~3. History of cluster or hemiplegic headache~4. Evidence of seizure or major psychiatric disorder~5. Score of 19 or higher on the BDI~6. Active chronic pain syndrome~7. Cardiac or hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AMG334 70 mg (Type: EXPERIMENTAL): AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
- AMG334 140 mg (Type: EXPERIMENTAL): AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Two pre-filled syringes containing placebo identical in appearance to erenumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 55 or older and providing at-home care for a care recipient (CR) with a physician-diagnosis of Alzheimer's disease (AD) or related dementia.~Exclusion Criteria:~* Receiving beta-blocking medications at enrollment~* Receiving treatment with Anticoagulant medications~* Severe hypertension (\>200/120 mmHg)~* Diagnosed with a terminal illness with a life expectancy \<6 months~* Enrolled in another intervention study

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pleasant Events Program (PEP) (Type: EXPERIMENTAL): The Pleasant Events Program (PEP) is a Behavioral Activation (BA) treatment for depression. Participants receive 4 weekly sessions of face-to-face therapy (60 minutes each) to increase caregiver participation in pleasurable activities. Two additional phone sessions focus on continued behavioral activation for caregivers as well as problem-solving barriers to activation.
- Information-Support (IS) (Type: ACTIVE_COMPARATOR): Participants in the Information-Support (IS) control condition were provided with a resource manual consisting of topics commonly covered in support groups or information packets provided by community agencies. Topics included problem-solving and communication skills, cognitive reframing and behavioral management, self-care help, caregiver fact sheets on a range of social and mental health issues, placement information, financial and legal issues, and lists of local organizations and community resources available. Each IS session allowed caregivers to select issue(s) from the resource manual to discuss. The therapist covered the material based on the caregivers' needs. When requested by the caregiver, supportive psychotherapy was also provided.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diabetes Prevention Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Impaired glucose tolerance (fasting plasma glucose 95-125 mg/dL and 2hr plasma glucose 140-199 mg/dL)~* BMI \>= 24 kg/m2~Exclusion Criteria:~* Underlying disease likely to limit life span and/or increase risk of interventions~* Conditions or behaviors likely to effect conduct of the DPP~* Diabetes or disordered glucose metabolism~* Suboptimally treated Thyroid disease~* Fasting triglyceride level \< 600 mg/dl~* Exclusions related to medications

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Metformin (Type: ACTIVE_COMPARATOR): None
- Intensive Lifestyle (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Adenocarcinoma of the prostate metastatic Age\> 18 years3.~* Life expectancy\> 12 months;~* Performance Index status \<3 PSA ≥ 4 ng / ml Zoledronic acid treatment in progress as recommended by the Authority for the Marketing Creatinine clearance above 30 ml / min Lack of maintenance causing disabling pain not lying down long (30 minutes) No history of radiotherapy to the region to be irradiated Absence of neurological signs compression Distance between the metastasis and spinal cord ≥ 5 mm Absence of metastases unstable metastatic epidural spinal cord compression or may require surgery before radiotherapy~Exclusion Criteria:~* Concomitant treatment with a drug testing, participation in another clinical trial within \<30 days~* Presence of central system nervous desease (symptoms or progressive), Patient with a severe neurological disease, current manifestations of peripheral neuropathy\> grade 2 NCI-CTC V4 Existence of another severe pulmonary disease, liver or kidney, digestive likely to be exacerbated by treatment,~* Untreated with zoledronic acid~* Treatment with a bisphosphonate other than Zoledronic acid~* Clinically significant hypersensitivity to zoledronic acid, other bisphosphonates or to any excipients in the formulation of Zometa.~* Creatinine clearance below 30 ml / min~* History of another primary cancer (except basal cell skin cancer)~* Or demented patient with altered mental status who can not obtain informed consent. / Persons deprived of liberty or under guardianship~* Pain not resulting in maintaining the prolonged supine position (30 minutes)~* PSA below 4 ng / ml~* History of radiotherapy in localized tumor site~* Distance between the metastasis and spinal cord \<5 mm~* Monitoring impossible because of psychological, sociological or because of geographical distance.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- irradiation + zometa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of a calcaneal, dorsal or plantar diabetic foot ulcer ≥ 2 cm2 in area after debridement. (If more than one ulcer is present, all wounds will be treated using the same method, but only one ulcer will be studied.)~* DFU equivalent to Stage 2 or greater, as defined by Wagner's Scale system (See Appendix E)~* Evidence of adequate perfusion by one of the following on the affected extremity,(within the past 60 days):Dorsum transcutaneous oxygen test (TcPO2) with results of ≥30 mmHg, or ABIs with results of ≥0.7 and ≤1.2 and toe pressures with results of ≥30 mmHg, or Doppler arterial waveforms, which are triphasic or biphasic at the ankle in the affected leg.~* Age ≥ 18 years of age~* HbA1c ≤ 12% (collected within the last 90 days.)~* Evidence of adequate nutrition by one of the following:~* Lab results reflecting Pre-Albumin \>16 mg/dl and Albumin level is \>3 g/dl (during the seven days prior to the study period), or a nutritional consult will be done and with appropriate supplementation started. Proper documentation on CRFs is needed.~Exclusion Criteria:~* Patients with recognized active Charcot abnormalities of the foot, as evidence by clinical symptoms that interfere with either randomized treatment group~* Ulcers resulting from electrical, chemical, or radiation burns, or venous insufficiency~* Untreated infection or cellulites at site of target ulcer~* Presence of untreated osteomyelitis~* Collagen vascular disease~* Malignancy in the ulcer~* Presence of necrotic tissue~* Uncontrolled hyperglycemia~* Concomitant medications that include (washout period of 30 days for corticosteroids, immunosuppressive medications, or chemotherapy)~* Open amputations~* Prior V.A.C. therapy within 30 days.~* Current or prior normothermic (Warm-UP®) or HBO therapy within 30 days.~* Current or prior treatment with recombinant or autologous growth factor products within the past 30 days. (Examples: Regranex or Procuren)~* Current or prior treatment with skin or dermal substitutes and dressings (Examples: Apligraft, Dermagraft, or Integra) with living cells capable of producing growth factors (Example: Oasis) within the past 30 days.~* Current use of any enzymatic debridment agent (Example: Acuzyme /Panafil) during the active treatment phase of the study~* Pregnant or nursing mothers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VAC Therapy (Type: EXPERIMENTAL): Treatment of Diabetic Foot Ulcers with VAC Therapy
- Moist Wound Therapy (Type: ACTIVE_COMPARATOR): Moist Wound Therapy (standard of care)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current male or female cigarette smokers who are motivated to stop smoking.~* Smoked an average of 10 cigarettes per day during past year and the month prior to first visit.~Exclusion Criteria:~* Patients who have used a nicotine replacement product, bupropion, clonidine or notriptyline within the past 6 months.~* Patients currently with depression or diagnosed with depression in past 12 months.~* Past or present history of psychosis, panic disorder, or bipolar disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- varenicline (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Study of Trabectedin in Soft Tissue Sarcomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who received trabectedin according to the approved indication in the period January 2010 December 2015~Exclusion Criteria:~* Trabectedin started before January 2010 and after December 2015~* Participation into clinical trials with trabectedin~* Clinical chart missing, empty, or not retrievable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trabectedin (Type: None): Trabectedin give according the market authorization for advanced soft tissue sarcoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Participants genetically diagnosed with hoFH.~* Participants treated with optimal dose of statin +/- other lipid modifying therapies (LMTs), or non-statin LMTs if statin-intolerant at stable dose(s) for at least 4 weeks.~* A signed informed consent indicating parental permission with or without participants assent.~* For participants on apheresis, currently undergoing stable LDL apheresis therapy prior to the screening visit (Week -2) and had initiated apheresis treatment for at least 6 months.~Exclusion criteria:~* Participants with LDL-C \<130 milligram per deciliter \[mg/dL\] (3.37 millimoles per liter \[mmol/L\]) obtained during the screening period after the participant had been on stable apheresis procedure or LMT (i.e., stable optimal dose of statin ± other stable LMTs, or stable non statin LMTs in statin-intolerant participants) treatment for at least 4 weeks.~* Participants with BW \<25 kg.~* Participants aged 8 to 9 years not at Tanner Stage 1 and participants aged of 10 to 17 years not at least at Tanner Stage 2 in their development.~* Participants with uncontrolled Type 1 or 2 diabetes mellitus.~* Participants with known uncontrolled thyroid disease.~* Participants with uncontrolled hypertension.~* Participants who will receive statin de novo during the run-in period.~* Fasting triglycerides greater than (\>) 350 mg/dL (3.95 mmol/L) at the screening visit.~* Severe renal impairment (i.e., estimated glomerular filtration rate \<30 milliliter per minute/1.73 meter square) at the screening visit.~* Alanine aminotransferase or aspartate aminotransferase \>2 \* upper limit of normal (ULN) at the screening visit.~* Creatine phosphokinase \>3 \* ULN at the screening visit.~The above information was not intended to contain all considerations relevant to a participants potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Alirocumab (Type: EXPERIMENTAL): Participants with BW less than (\<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 75 mg Q2W for 48 weeks. Alirocumab dose was up-titrated to 150 mg Q2W from Week 12 in case of increase in BW with BW greater than or equal to \[\>=\] 50 kg.~Participants with BW \>=50 kg received SC injection of alirocumab 150 mg Q2W for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically diagnosed patients who have more than three warts or single wart in difficult to treat sites (periungual, palms and soles)~Exclusion Criteria:~1. Patients not under any systemic or topical treatment of warts for the last four weeks~2. Patients with a past history of an allergic response to MMR or any other vaccine or Vitamin D~3. Patients with current acute febrile illness or any bacterial infection~4. Immunosuppressed patients~5. Pregnant or lactating women~6. Patients having a past history of asthma, allergic skin disorders or convulsions~7. Patients with keloidal tendency~8. Patient refusal for consent~9. Treating physician's decision to give other treatment modality~10. Patients with hypervitaminosis D, muscle weakness, bone pain, altered sensorium

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Measles, Mumps, Rubella vaccine (Type: EXPERIMENTAL): All Group A patients will receive intralesional MMR.
- Vitamin D3 (Type: EXPERIMENTAL): All Group B patients will receive intralesional Vitamin D3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete